Abingworth has raised $115.3 million for its Abingworth Bioventures VII, according to a SEC filing. The London-headquartered firm began fundraising in 2016 with a $400 million target.
Its previous fund raised $225 million in 2014.
The fund will target venture capital opportunities in biotech and healthcare sectors in Europe.
